Teva Pharmaceutical Industries’ (TEVA) “Hold” Rating Reaffirmed at Oppenheimer
Several other research firms have also commented on TEVA. BTIG Research raised shares of Teva Pharmaceutical Industries from a sell rating to a neutral rating in a research report on Monday, September 17th. Citigroup set a $25.00 price target on shares of Teva Pharmaceutical Industries and gave the company a buy rating in a research report on Thursday, May 31st. Barclays set a $23.00 price target on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Thursday, August 2nd. Mizuho reaffirmed a buy rating and set a $27.00 price target on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 2nd. Finally, Cantor Fitzgerald set a $25.00 price target on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Friday, July 13th. Seven analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $21.11.
Shares of NYSE:TEVA opened at $24.36 on Thursday. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $25.96. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $24.77 billion, a price-to-earnings ratio of 6.20, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69.
In other news, EVP Sven Dethlefs bought 2,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 3rd. The stock was bought at an average cost of $21.92 per share, with a total value of $43,840.00. Following the acquisition, the executive vice president now owns 6,445 shares of the company’s stock, valued at approximately $141,274.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total transaction of $56,334.96. Following the completion of the sale, the insider now directly owns 2,376 shares of the company’s stock, valued at $56,334.96. The disclosure for this sale can be found here. Insiders sold a total of 10,350 shares of company stock valued at $239,430 over the last three months. 0.43% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Global Financial Private Capital LLC boosted its stake in Teva Pharmaceutical Industries by 92.2% in the 2nd quarter. Global Financial Private Capital LLC now owns 23,632 shares of the company’s stock worth $575,000 after purchasing an additional 11,335 shares during the period. Sei Investments Co. boosted its stake in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. Sei Investments Co. now owns 162,241 shares of the company’s stock worth $3,946,000 after purchasing an additional 34,305 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in Teva Pharmaceutical Industries by 553.3% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 22,361 shares of the company’s stock worth $544,000 after purchasing an additional 18,938 shares during the period. Toronto Dominion Bank bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $669,000. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Teva Pharmaceutical Industries by 25.5% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 83,473 shares of the company’s stock worth $2,030,000 after purchasing an additional 16,946 shares during the period. 64.52% of the stock is owned by institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: Index Funds
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.